These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 18393977)
1. Genetic alterations of CCND1 and EMSY in breast cancers. Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977 [TBL] [Abstract][Full Text] [Related]
2. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701 [TBL] [Abstract][Full Text] [Related]
3. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470 [TBL] [Abstract][Full Text] [Related]
4. The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis. Baykara O; Dalay N; Bakir B; Bulut P; Kaynak K; Buyru N Int J Med Sci; 2017; 14(7):675-679. PubMed ID: 28824300 [No Abstract] [Full Text] [Related]
5. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351 [TBL] [Abstract][Full Text] [Related]
6. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566 [TBL] [Abstract][Full Text] [Related]
7. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907 [TBL] [Abstract][Full Text] [Related]
8. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065 [TBL] [Abstract][Full Text] [Related]
9. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations. Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328 [TBL] [Abstract][Full Text] [Related]
10. Functional characterization of EMSY gene amplification in human cancers. Wilkerson PM; Dedes KJ; Wetterskog D; Mackay A; Lambros MB; Mansour M; Frankum J; Lord CJ; Natrajan R; Ashworth A; Reis-Filho JS J Pathol; 2011 Sep; 225(1):29-42. PubMed ID: 21735447 [TBL] [Abstract][Full Text] [Related]
12. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530 [TBL] [Abstract][Full Text] [Related]
13. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860 [TBL] [Abstract][Full Text] [Related]
15. RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial. Keilty D; Buchanan M; Ntapolias K; Aleynikova O; Tu D; Li X; Shepherd L; Bramwell V; Basik M PLoS One; 2013; 8(12):e81740. PubMed ID: 24367492 [TBL] [Abstract][Full Text] [Related]
16. Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs. Benusiglio PR; Lesueur F; Luccarini C; McIntosh J; Luben RN; Smith P; Dunning A; Easton DF; Ponder BA; Pharoah PD BMC Cancer; 2005 Jul; 5():81. PubMed ID: 16029503 [TBL] [Abstract][Full Text] [Related]
17. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415 [TBL] [Abstract][Full Text] [Related]
19. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection]. Mrhalová M; Kodet R; Strnad P Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908 [TBL] [Abstract][Full Text] [Related]
20. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]